Jazz Pharma Q1 2026: Record Revenue, Pipeline Advancements

Jazz Pharmaceuticals Q1 2026 earnings shatter records with $1.1 billion revenue, up 19% from last year. Key drivers: Xywav at $408 million, Epidiolex at $250 million, and Zepzelca up 60% to $101 million. Non-GAAP adjusted earnings per share at $6.34 and over $400 million cash flow. Commercial teams excelled in sleep, epilepsy, and oncology, adding 425 new Xywav patients. Oncology standouts: Midevo at $41 million and ZYHERA at $13 million, prepping for expansion. Physicians praise ZYHERAs potential in HER2-positive gastric esophageal adenocarcinoma. FDA granted priority review to ZYHERAs supplemental application, with a decision due August 25, 2026. Multiple trials for zanidatumab advance in breast cancer and beyond. Jazz reaffirms full-year revenue guidance of $4.25-$4.5 billion, focusing on approvals, data readouts, and smart investments in rare diseases. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a125f7ed9d585215